METABOLISM OF A NOVEL ANTIARRHYTHMIC AGENT, BIDISOMIDE, IN MAN - USE OF HIGH-RESOLUTION MASS-SPECTROMETRY TO DISTINGUISH DESISOPROPYL BIDISOMIDE FROM DESACETYL BIDISOMIDE
Cs. Cook et al., METABOLISM OF A NOVEL ANTIARRHYTHMIC AGENT, BIDISOMIDE, IN MAN - USE OF HIGH-RESOLUTION MASS-SPECTROMETRY TO DISTINGUISH DESISOPROPYL BIDISOMIDE FROM DESACETYL BIDISOMIDE, Xenobiotica, 25(9), 1995, pp. 981-991
1. Metabolism of bidisomide, a novel antiarrhythmic agent, was studied
in man, and was not extensive as evidenced by the fact that approxima
tely 60 and 70% of the radioactive doses were recovered as the parent
drug after i.v. and oral administration respectively. 2. The mass spec
tra of bidisomide metabolites indicate that the two major metabolic pa
thways of bidisomide were hydroxylation of the piperidine ring and N-d
ealkylation. The latter occurred on the side chain containing the pipe
ridine ring or the isopropyl group. The N-dealkylated metabolite on th
e side chain containing the piperidine ring was cyclized to result in
a pyrrolidone metabolite. 3. The N-dealkylated metabolite, desisopropy
l bidisomide, was identified by comparing its high resolution mass spe
ctrum to that of authentic desacetyl bidisomide. 4. In the hydroxylati
on pathway, both mono- and dihydroxylated metabolites of the piperidin
e ring were observed. The exact location of the hydroxyl groups on the
piperidine ring was not determined.